Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10351 - 10375 of 12433 in total
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol.
Experimental
Matched Description: … It is also a positional isomer of estriol. [A31630] ... 2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol …
Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia).
Investigational
Matched Description: … Another Antibiotic in the Treatment of Community Acquired Pneumonia). ... Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus …
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID- …
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Investigational
Matched Description: … Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of
Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).
Investigational
Matched Description: … VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty). ... Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Matched Description: … for the treatment of immune disorders, such as immune thrombocytopenic purpura. ... Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated …
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
Investigational
Matched Description: … Food on the Pharmacokinetics of the 2 New Concept Formulations). ... is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of ... Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct...
Investigational
Matched Description: … the sporadic form of Parkinson's disease. ... link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. ... In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular …
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of...
Investigational
Matched Description: … type 2 diabetes are resistant to the effects of insulin. ... These people are said to be resistant to the effects of leptin, in much the same way that people with ... signal that reduces appetite, in general, obese people have an unusually high circulating concentration of
Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus). Shark oil is a rich source of...
Experimental
Matched Description: … Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body ... Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated ... However the major component is considered to be squalene, which may range up to 90% of the shark oil, …
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … in individuals with low levels of Mannose-Binding Lectin (MBL). ... Over 10 percent of the general population is estimated to be MBL-deficient. ... Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. …
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. ... It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. …
Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM).
Investigational
Matched Description: … Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). ... Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Investigational
Matched Description: … and metabolic status of Candida albicans cells within biofilms. ... Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology …
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … for the treatment of non-Hodgkin's lymphoma. ... Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … Different Formulations Of PF-04937319 In Healthy Subjects). ... 04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … A Modified Release Formulation of PF-06650833 in Healthy Subjects). ... PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of
Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).
Investigational
Matched Description: … , Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma). ... Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics …
Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-type Headache).
Investigational
Matched Description: … TNX-201 Capsules for Treatment of Single Tension-type Headache). ... Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of
Displaying drugs 10351 - 10375 of 12433 in total